Ocugen is a biotechnology business based in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Ocugen employs 56 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $1.24 |
|---|---|
| 52-week range | $1.09 - $4.53 |
| 50-day moving average | $1.37 |
| 200-day moving average | $2.02 |
| Wall St. target price | $5.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.35 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.24 from 2023-02-07
| 1 week (2023-02-01) | -2.36% |
|---|---|
| 1 month (2023-01-06) | -4.62% |
| 3 months (2022-11-08) | -24.39% |
| 6 months (2022-08-08) | -56.49% |
| 1 year (2022-02-04) | -65.46% |
|---|---|
| 2 years (2021-02-08) | -92.16% |
| 3 years (2020-02-07) | 142.80% |
| 5 years (2018-02-08) | 154.2 |
| Gross profit TTM | $-35,108,000 |
|---|---|
| Return on assets TTM | -40.47% |
| Return on equity TTM | -73.11% |
| Profit margin | 0% |
| Book value | $0.44 |
| Market capitalisation | $278 million |
TTM: trailing 12 months
We're not expecting Ocugen to pay a dividend over the next 12 months.
Ocugen's shares were split on a 1:60 basis on 29 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.
Over the last 12 months, Ocugen's shares have ranged in value from as little as $1.09 up to $4.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocugen's is 3.8845. This would suggest that Ocugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Ocugen, Inc. , a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
